Corcept shares rise on positive Phase 3 trial results

Corcept Therapeutics (CORT) shares rose 5.8% after positive Phase 3 ROSELLA trial data, presented at ASCO 2025 and published in The Lancet, showed relacorilant combined with nab-paclitaxel significantly improved progression-free survival and overall survival in platinum-resistant ovarian cancer patients. The combination therapy demonstrated a 30% reduction in disease progression risk and extended median overall survival to 16.0 months versus 11.5 months with nab-paclitaxel alone, with a comparable safety profile. Corcept is now pursuing regulatory approvals in the U.S. and Europe, positioning relacorilant as a potential new standard of care.

Analysis

Corcept Therapeutics (CORT) stock registered a 5.8% appreciation following the disclosure of positive data from its pivotal Phase 3 ROSELLA trial at the ASCO 2025 Annual Meeting. The trial, assessing relacorilant combined with nab-paclitaxel for platinum-resistant ovarian cancer, met its primary endpoint of improved progression-free survival (PFS) as determined by blinded independent central review (PFS-BICR). Patients administered the relacorilant combination experienced a 30% reduction in the risk of disease progression, achieving a median PFS-BICR of 6.5 months versus 5.5 months in the nab-paclitaxel monotherapy arm. Importantly, interim overall survival (OS) data also showed a significant benefit, with a median OS of 16.0 months for the combination group compared to 11.5 months for the monotherapy group. The safety profile of the relacorilant combination was found to be comparable to that of nab-paclitaxel alone and was well-tolerated, with patients on the combination therapy also reporting a lower incidence of ascites and requiring fewer abdominal paracenteses, indicating an improved quality of life. The results, published in The Lancet, suggest relacorilant could establish a new standard of care in this indication. Corcept Therapeutics is now proceeding with regulatory applications in the U.S. and Europe, aiming to expedite patient access to this treatment, which underscores the potential of modulating cortisol activity in tumors expressing the glucocorticoid receptor. The trial involved 381 patients, and achieving statistical significance on either of the dual primary endpoints (PFS-BICR or OS) was considered a positive outcome.

Key Decisions for Investors

• The robust Phase 3 data significantly de-risks relacorilant for platinum-resistant ovarian cancer and presents a strong positive catalyst for Corcept Therapeutics, justifying the market's optimistic reaction.
• Investors should monitor upcoming regulatory filings and subsequent decisions in the U.S. and Europe, as approvals would likely unlock significant commercial value and potential further stock appreciation.
• Given relacorilant's potential to become a new standard-of-care, alongside a favorable safety profile and quality of life benefits, the long-term revenue prospects appear promising, though successful commercial execution remains a key factor to observe.